Careers

Careers

Passionate to help us save lives?

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia
Trimodulin (BT588) - "Severe" COVID-19
Haemophilia A Therapeutic (HAT) - Haemophilia A

Pipeline

Pipeline

Press releases

Strategic agreement signed for distribution of Yimmugo®...

02.10.2024,

02.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Change in the Chief Financial Officer at Biotest AG

12.09.2024,

12.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG opens 13th plasma collection center in Germa...

05.09.2024,

05.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Dr. Jörg Schüttrumpf resigns from the Management Board ...

28.08.2024,

28.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increases sales in the first half of 2024 by 35...

06.08.2024,

06.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increases sales in the first half of 2024 by 35...

30.07.2024,

30.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

29.07.2024,

29.07.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest prepares launch of its immunoglobulin Yimmugo i...

01.07.2024,

01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest's sustainability campaign GoFuture part of the ...

24.06.2024,

24.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Milestone for Biotest: US approval for innovative immun...

17.06.2024,

17.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increased sales by 83.6% to Euro 215.2 million ...

07.05.2024,

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Annual General Meeting approves dividend distribution

07.05.2024,

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG opens 12th plasma collection centre in Germa...

19.04.2024,

19.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG increased sales by 32% in the financial year...

28.03.2024,

28.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest achieves EBIT forecast for 2023

29.02.2024,

29.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Karl Lauterbach visits Biotest AG's plasma donation cen...

28.02.2024,

28.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest successfully meets primary endpoint in phase II...

14.02.2024,

14.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

30.01.2024,

30.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Preliminary announcement of the publication of financia...

22.01.2024,

22.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest AG opens 11th plasma collection centre in Germa...

18.01.2024,

18.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Renate & Hans Schleussner Award

Renate & Hans Schleussner Award

Third Renate & Hans Schleussner Research Award 2023/2024 on Hyper-Immunoglobulins now online.